We previously found that one third of nonmetastatic breast cancer patients had sarcopenia (age-related loss of muscle tissue) at the time of their diagnosis and that having sarcopenia and obesity was associated with an 89% increased risk of death. This study will use 1,400 archived clinical tumor tissues from stage II-III breast cancer patients for whom we have data on body composition, metabolic syndrome, weight history, cancer therapy, and long-term follow-up for breast cancer outcomes. We will classify breast cancer molecular subtypes, measure gene expression levels in immune and metabolic pathways potentially influenced by body composition and the metabolic syndrome, and examine whether alterations in the breast cancer tumor microenvironment mediate the association of body composition and breast cancer survival.
Body Composition and Breast Cancer Survival: Immune and Metabolic Biomarkers in Breast Tumors
Investigator: Feliciano, Elizabeth
Funder: National Cancer Institute